{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:28:02Z","timestamp":1789421282963,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T00:00:00Z","timestamp":1473811200000},"content-version":"vor","delay-in-days":349,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.det.2015.05.010","type":"journal-article","created":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T16:39:38Z","timestamp":1440866378000},"page":"757-764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Madeleine","family":"Duvic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2015.05.010_bib1","first-page":"2212","article-title":"Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas","volume":"95","author":"Vergier","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.010_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4155\/fmc.12.6","article-title":"HDAC Inhibitors for the treatment of cutaneous T-cell lymphomas","volume":"4","author":"Rangwalla","year":"2012","journal-title":"Future Med Chem"},{"key":"10.1016\/j.det.2015.05.010_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/0973-1482.137937","article-title":"Epigenetic therapy of cancer with histone deacetylase inhibitors","volume":"10","author":"Lakshmaiah","year":"2014","journal-title":"J\u00a0Cancer Res Ther"},{"key":"10.1016\/j.det.2015.05.010_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.det.2015.05.010_bib5","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.4161\/15592294.2014.971580","article-title":"Chromatin regulation: how complex does it get?","volume":"9","author":"Meier","year":"2014","journal-title":"Epigenetics"},{"issue":"7","key":"10.1016\/j.det.2015.05.010_bib6","doi-asserted-by":"crossref","first-page":"e68915","DOI":"10.1371\/journal.pone.0068915","article-title":"Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma","volume":"8","author":"Wells","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.det.2015.05.010_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1615\/CritRevOncog.2014012484","article-title":"HDAC6-dependent functions in tumor cells: crossroad with the MAPK pathways","volume":"20","author":"Haakenson","year":"2015","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.det.2015.05.010_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1369\/0022155413506582","article-title":"Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer","volume":"62","author":"Parbin","year":"2014","journal-title":"J\u00a0Histochem Cytochem"},{"key":"10.1016\/j.det.2015.05.010_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.010_bib10","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"A\u00a0phase IIb multicenter trial of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with persistent, progressive, or treatment refractory mycosis fungoides or sezary syndrome subtypes of cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J\u00a0Clin Onc"},{"key":"10.1016\/j.det.2015.05.010_bib11","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2559.2009.03290.x","article-title":"Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas","volume":"54","author":"Marquard","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.det.2015.05.010_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-5-24","article-title":"Novel therapeutic agents for cutaneous T-Cell lymphoma","volume":"5","author":"Jain","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.det.2015.05.010_bib13","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.molonc.2014.05.001","article-title":"Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin","volume":"8","author":"Luchenko","year":"2014","journal-title":"Mol Oncol"},{"issue":"6638","key":"10.1016\/j.det.2015.05.010_bib14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/40657","article-title":"Inhibition of death receptor signals by cellular FLIP","volume":"388","author":"Irmler","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.det.2015.05.010_bib15","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1038\/sj.onc.1203176","article-title":"Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2\/Bcl-XL, c-Jun, and p21CIP1, but independent of p53","volume":"18","author":"Vrana","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.det.2015.05.010_bib16","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.4161\/15384101.2014.947759","article-title":"Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines","volume":"13","author":"Litvinov","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.det.2015.05.010_bib17","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.det.2015.05.010_bib18","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","article-title":"Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor","volume":"95","author":"Richon","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.det.2015.05.010_bib19","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.bjc.6603464","article-title":"Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma","volume":"95","author":"O'Connor","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.det.2015.05.010_bib20","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1476-5381.2010.01188.x","article-title":"The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells","volume":"162","author":"Tiffon","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.det.2015.05.010_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4161\/cc.4.4.1564","article-title":"Histone deacetylase inhibitors in programmed cell death and cancer therapy","volume":"4","author":"Marks","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.det.2015.05.010_bib22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.det.2015.05.010_bib23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1358\/dot.2007.43.9.1112980","article-title":"Vorinostat in cutaneous T-cell lymphoma","volume":"43","author":"Duvic","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.det.2015.05.010_bib24","first-page":"377","article-title":"Update on the treatment of cutaneous T-cell lymphoma (CTCL): focus on vorinostat","volume":"1","author":"Duvic","year":"2007","journal-title":"Biol Targets Ther"},{"key":"10.1016\/j.det.2015.05.010_bib25","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.010_bib26","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A\u00a0phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.det.2015.05.010_bib27","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","article-title":"Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in\u00a0vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition","volume":"53","author":"Dummer","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.det.2015.05.010_bib28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CAD.0000000000000183","article-title":"Cyclic depsipeptides as potential cancer therapeutics","volume":"26","author":"Kitagaki","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.det.2015.05.010_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.010_bib30","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.010_bib31","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.010_bib32","article-title":"Romidepsin (depsipeptide) induces clinically significant responses in treatment-refractory CTCL: an international study","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.010_bib33","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.010_bib34","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","article-title":"T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance","volume":"103","author":"Piekarz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.010_bib35","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.010_bib36","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1345\/aph.1R036","article-title":"Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma","volume":"46","author":"Kim","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.det.2015.05.010_bib37","doi-asserted-by":"crossref","first-page":"30937","DOI":"10.1074\/jbc.M110.212035","article-title":"Histone deacetylase inhibitor belinostat represses surviving expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death J","volume":"286","author":"Chowdhury","year":"2011","journal-title":"Biol Chem"},{"key":"10.1016\/j.det.2015.05.010_bib38","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","article-title":"1543-1554 Belinostat: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.det.2015.05.010_bib39","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"Phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.det.2015.05.010_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.8580","article-title":"Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma","volume":"27","author":"Zain","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.010_bib41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1200\/jco.2007.25.18_suppl.14092","article-title":"A\u00a0phase I study of oral belinostat (PXD101) in patients with advanced solid tumors","volume":"25","author":"Kelly","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.010_bib42","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s10637-013-9930-2","article-title":"A\u00a0phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors","volume":"31","author":"Sharma","year":"2013","journal-title":"Invest New Drugs"},{"issue":"9","key":"10.1016\/j.det.2015.05.010_bib43","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.2013.815165","article-title":"Panobinostat in lymphoid and myeloid malignancies","volume":"22","author":"Khot","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.det.2015.05.010_bib44","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -na\u00efve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial","volume":"42","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T14:55:10Z","timestamp":1691938510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863515000558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0733863515000558"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2015.05.010","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2015.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}